These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 37140823)

  • 41. [Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].
    Santoro A; Mandreoli M
    G Ital Nefrol; 2018 May; 35(3):. PubMed ID: 29786183
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hyperkalaemia in Heart Failure: Consequences for Outcome and Sequencing of Therapy.
    Murphy D; Banerjee D
    Curr Heart Fail Rep; 2022 Aug; 19(4):191-199. PubMed ID: 35704263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacological interventions for heart failure in people with chronic kidney disease.
    Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
    Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL.
    Ferreira JP; Konstam M; Rossignol P; Kiernan MS; Zannad F
    J Card Fail; 2023 Jan; 29(1):45-52. PubMed ID: 36244652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality.
    Beusekamp JC; Tromp J; Cleland JGF; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Ouwerkerk W; van Veldhuisen DJ; Voors AA; van der Meer P
    JACC Heart Fail; 2019 Nov; 7(11):970-979. PubMed ID: 31606364
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and Safety of Patiromer in Hyperkalemia: A Systematic Review and Meta-Analysis.
    Das S; Dey JK; Sen S; Mukherjee R
    J Pharm Pract; 2018 Feb; 31(1):6-17. PubMed ID: 28402156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis.
    Shrestha DB; Budhathoki P; Sedhai YR; Baniya R; Cable CA; Kashiouris MG; Dixon DL; Kidd JM; Adhikari Y; Marasini A; Bhandari S
    Curr Ther Res Clin Exp; 2021; 95():100635. PubMed ID: 34367383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimally managing hyperkalemia in patients with cardiorenal syndrome.
    Wang AY
    Nephrol Dial Transplant; 2019 Dec; 34(Suppl 3):iii36-iii44. PubMed ID: 31800079
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hyperkalemia in heart failure: current treatment and new therapeutic perspectives.
    Minà C; Ajello L; Gesaro GD; Falletta C; Clemenza F
    Rev Cardiovasc Med; 2020 Jun; 21(2):241-252. PubMed ID: 32706212
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A; Hanna RM; Mkrttchyan A; Khalid M; Yaqoob S; Shaffer K; Dhawan P; Nobakht N; Kamgar M; Goshtaseb R; Sarmosyan K; Gnarini M; Wassef O; Lerma E
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1055-1064. PubMed ID: 34227913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K
    Murphy D; Ster IC; Kaski JC; Anderson L; Banerjee D
    BMC Nephrol; 2021 Jul; 22(1):254. PubMed ID: 34229607
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in treatment of hyperkalemia in chronic kidney disease.
    Sarafidis PA; Georgianos PI; Bakris GL
    Expert Opin Pharmacother; 2015; 16(14):2205-15. PubMed ID: 26330193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Management of hyperkalemia in chronic heart failure using sodium zirconium cyclosilicate.
    Oshima A; Imamura T; Narang N; Kinugawa K
    Clin Cardiol; 2021 Sep; 44(9):1272-1275. PubMed ID: 34263946
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.
    Weir MR; Rolfe M
    Clin J Am Soc Nephrol; 2010 Mar; 5(3):531-48. PubMed ID: 20150448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Implications of Sodium Zirconium Cyclosilicate Therapy in Patients with Systolic Heart Failure and Hyperkalemia.
    Imamura T; Oshima A; Narang N; Kinugawa K
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
    Butler J; Anker SD; Siddiqi TJ; Coats AJS; Dorigotti F; Filippatos G; Friede T; Göhring UM; Kosiborod MN; Lund LH; Metra M; Moreno Quinn C; Piña IL; Pinto FJ; Rossignol P; Szecsödy P; Van Der Meer P; Weir M; Pitt B
    Eur J Heart Fail; 2022 Jan; 24(1):230-238. PubMed ID: 34800079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Hyperkalemia in heart failure: etiology, epidemiology and prognosis].
    Romani S; Sinagra G
    G Ital Cardiol (Rome); 2021 Dec; 22(12 Suppl 1):e3-e7. PubMed ID: 34935773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cost analysis of patiromer vs sodium zirconium cyclosilicate for the treatment of hyperkalemia in Spain and the UK.
    Ramirez de Arellano A; Jakutis G; Hunt B
    J Med Econ; 2024; 27(1):1011-1017. PubMed ID: 39023516
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.